sorafenib has been researched along with 1,6-anhydro-3,4-dideoxy-beta-d-glycero-hex-3-enopyran-2-ulose in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (1,6-anhydro-3,4-dideoxy-beta-d-glycero-hex-3-enopyran-2-ulose) | Trials (1,6-anhydro-3,4-dideoxy-beta-d-glycero-hex-3-enopyran-2-ulose) | Recent Studies (post-2010) (1,6-anhydro-3,4-dideoxy-beta-d-glycero-hex-3-enopyran-2-ulose) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 33 | 0 | 24 |
| Protein | Taxonomy | sorafenib (IC50) | 1,6-anhydro-3,4-dideoxy-beta-d-glycero-hex-3-enopyran-2-ulose (IC50) |
|---|---|---|---|
| NACHT, LRR and PYD domains-containing protein 3 | Mus musculus (house mouse) | 1.2 | |
| NACHT, LRR and PYD domains-containing protein 3 | Homo sapiens (human) | 6.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Danielli, M; Giri, GF; Marinelli, RA; Spanevello, RA | 1 |
1 other study(ies) available for sorafenib and 1,6-anhydro-3,4-dideoxy-beta-d-glycero-hex-3-enopyran-2-ulose
| Article | Year |
|---|---|
Cytotoxic effect of levoglucosenone and related derivatives against human hepatocarcinoma cell lines.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Glucose; Humans; Liver Neoplasms | 2016 |